“Dupilumab Is a Predominant Treatment for Recalcitrant Bullous Pemphigoid”. Archives of Clinical Case Reports 4, no. 1 (February 24, 2021): 1–4. Accessed September 14, 2026. https://somatopub.com/index.php/ACCR/article/view/17.